Incretin enhancers, incretin mimetics - From therapeutic concept to clinical application;Inkretin hatáserosítok, inkrètin mimetikumok - A terápiás alkalmazás kigondolásától a gyakorlati megvalósításig

Orvosi Hetilap

Volumn 148, Issue 13, 2007, Pages 579-587

  Winkler, Gábor ^a,b  

^a ST JOHN'S HOSPITAL   (Hungary)

^b NONE   (Hungary)

Author keywords

Beta and alfa cell function; Dipeptidyl peptidase IV; Exenatide; GLP 1 enhancers; Incretin mimetics; Incretins; Sitagliptin; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INCRETIN ENNHANCER; INCRETIN MIMETIC; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN; ADAMANTANE; ADENOSINE DEAMINASE; DPP4 PROTEIN, HUMAN; DRUG DERIVATIVE; GASTROINTESTINAL HORMONE; GLYCOPROTEIN; NITRILE; PEPTIDE; PEPTIDE HORMONE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VENOM;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETOGENESIS; DRUG DOSE COMPARISON; DRUG SYNTHESIS; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; ANIMAL; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; INTESTINE; METABOLISM; REVIEW;

ADAMANTANE; ADENOSINE DEAMINASE; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTESTINES; NITRILES; PEPTIDE HORMONES; PEPTIDES; PYRAZINES; PYRROLIDINES; TRIAZOLES; VENOMS;

EID: 34547437346     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2007.28093     Document Type: Article

References (50)

1. Hansotia, T., Drucker, D. J.: GIP and GLP-1, as inrecitin hormones, lessons from single and double inrecitin receptor knockout mice. Regul. Pept. 2005, 128, 125-134.
2. Holst, J. J.: Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-inhibitors. Exp. Opin. Emerg. Drugs, 2004, 9, 155-166.
3. Winkler G., Cseh K.: A glukagonszerü peptid (GLP)-1 részvétele a szénhidrát-anyagcsere szábályozásában, receptor agonistái és analógjai potenciális helye a 2-es típusú diabetes mellims jövobeni terápiájában. Diabetol. Hung., 2002, 12, 187-197.
4. Winkler G., Cseh K.: Az inkretinmimetikum exenatid - új kezelési lehetoség a 2-es típusú diabetesben. Diabetol. Hung., 2005, 13 (Suppl. 3), 20-29.
5. Gastaldelli, A., Ferrannini, E., Miyazaki, Y. és mtsai: Betacell dysfunction and glucose intolerance: results from the San Antonio Metabolism (SAM) Study. Diabetologia, 2004, 47, 31-39.
6. Gerich, J. E.: Contributions of insulin-resistance, an insulinsecretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin. Proc., 2003, 78, 447-456.
7. Vieira, E., Salehi, A., Gylfe, E.: Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia, 2007, 50, 370-379.
8. Dunning, B. E., Foley, J. E., Ahrén, B.: Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia, 2005, 48, 1700-1713.
9. Meier, J. J., Kjems, L. L., Veldhuis, J. D. és mtsai: Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion. Further evidence for the intraislet hypothesis. Diabetes, 2006, 55, 1051-1056.
10. Lefébvre, P.: Alpha-cell function in type 2 diabetes. European Endocrine Disease, 2006. pp. 3-4 (www.touchbriefings. com).
11. Del Prato, S., Marchetti, P.: Beta- and alpha cell dysfunction in type 2 diabetes. Horm. Metab. Res., 2004, 36, 775-781.
12. Meneilly, G. S, Veldhuis, J. D., Elahi, D.: Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with Type 2 diabetes. J. Clin. Endocr. Metab., 2005, 90, 6251-6256.
13. Drucker, D, J.: The biology of incretine hormones. Cell. Metab., 2006, 3, 153-165.
14. Gautier, J. F., Fetita, S., Sobngwi, E. és mtsai: Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab., 2005, 31, 233-242.
15. Holst, J.: Glucagon-like peptide-l: from extract to agent. The Claude Bernard Lecture. Diabetologia, 2006, 49, 253-260.
16. Vilsbøll, T., Krarup, T., Madsbad, S. és mtsai: Both GLP-1 and GIP are insulinotropic at basal at postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept., 2003, 114, 115-121.
17. Mannucci, E., Pala, L., Ciani, S. és mtsai: Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia, 2005, 48, 1168-1172.
18. Drucker, D. J, Nauck, M. A.: The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368, 1696-1705.
19. Weber, A. E.: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem., 2004, 47, 4135-4141.
20. Charbonnel, B., Karasik, A., Liu, J. és mtsai (for the Sitagliptin Study 020 Group): Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagpliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care, 2006, 29, 2638-2643.
21. Holst, J. J., Deacon, C. F.: Glucagon-like peptide-1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr. Opin. Pharmacol., 2004, 4, 589-596.
22. Pospisilik, J. A., Martin, J., Doty, T. és mtsai: Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes, 2003, 52, 741-750.
23. Mu, J., Woods, J., Zhou, Y-P. és mtsai: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes, 2006, 55, 1695-704.
24. Xu, L., Kaneto, H., Lopez-Avalos, M. D. és mtsai: GLP1/ exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts. Diab. Res. Clin. Pract., 2006, 3, 107-110.
25. Deacon, C. F, Ahrén, B., Holst, J. J.: Inhibition of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes. Exp. Opin. Invest. Drugs, 2004, 13, 1091-1102.
26. Alarcon, C., Wicksteed, B., Rhodes, C. J.: Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia, 2006, 49, 2920-2929.
27. Simonsen, L., Holst, J. J., Deacon, C. F.: Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia, 2006, 49, 706-712.
28. Degn, K. B. J., Sturis, C. B., Jakobsen, J. és mtsai: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes, 2004, 53, 1187-1194.
29. Bergman, A. J., Stevens, C., Zhou, Y. Y. és mtsai: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind randomized, placebo-controlled study in healthy male volunteers. Clin. Ther., 2006, 28, 55-72.
30. Kim, D., Wang, L., Beconi, M. és mtsai: (2R)-4-oxo-4 [3-(trifluoromethyl)-5,6-dihydro/1,2,4/triazolo/4,3-a/pyrazin-7 (8H)-yl-] 1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2005, 48, 141-151.
31. Lankas, G. R., Leiting, B., Roy, B. S. és mtsai: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes, 2005, 54, 2988-2994.
32. Herman, G. A, Bergman, A., Liu, F. és mtsai: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J. Clin. Pharmacol., 2006, 46, 876-886.
33. Raz, I., Hanefeld, M., Xu, L. és mtsai (for the Sitagliptin Study 023 Group): Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia, 2006, 49, 2564-2571.
34. Nathan, D. M, Buse, J. B., Davidson, M. B. és mtsai: Management of chronic hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2006, 49, 1711-1721.
35. Rosenstock, J., Brazg, R., Andryuk, P. J. és mtsai (for the Sitagliptin Study 019 Group): Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther., 2006, 28, 1556-1568.
36. Henness, S., Keam, S. J.: Vildaliptin. Drugs, 2006, 66, 1989-2001.
37. Brandt, L, Joossens, J., Chen, X. és mtsai: Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation oy vildagliptin ((2S- [(3-hydroxyadamantan- 1-yl)amino]acetyl-pyrrolidine-2-carbonitrile). Biochem. Pharmacol., 2005, 70, 134-143.
38. Mari, A., Sallas, W. M., He, Y. L. és mtsai: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2005, 90, 4858-4864.
39. Ristic, S., Byiers, S., Foley, J. és mtsai: Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildaghptin (LAF237) dose response. Diab. Obes. Metab., 2005, 7, 692-698.
40. Ahrén, B., Gomis, R., Standl, E. és mtsai: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care, 2004, 27, 2874-2880.
41. Ahrén, B., Landin-Olsson, M., Jansson, P-A. és mtsai: Inhibition of dipeptidy peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocr. Metab., 2004, 89, 2078-2084.
42. Mentlein, R.: Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept., 1999, 85, 9-24.
43. Roges, O. A., Baron, M., Philis-Tsimikas, A.: The incretin effect and its potentiation by glucagon-like peptide-l-based therapies: a revolution in diabetes management. Exp. Opin. Investig. Drugs, 2005, 14, 705-727.
44. Buse, J. B, Henry, R. R., Chan, J. és mtsai (for the Exenatide-113 Clinical Study Group): Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-patients with type 2 diabetes. Diabetes Care, 2004, 27, 2628-2635.
45. DeFronzo, R. A., Rainer, R. E., Han, J. és mtsai: Effects of exenatide (exendin-4) on glycemic control and weight gain over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 2005, 28, 1092-1100.
46. Blonde, L., Klein, E. J., Han, J. és mtsai: Interim analysis of the effects of exenatide treatment on Alc, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diab. Obes. Metab., 2006, 8, 436-447.
47. Heine, R., Van Gaal, L. F., Mibm, M. J. és mtsai (for the GWAA Study Group): Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann. Intern. Med., 2005, 143, 559-569.
48. Nauck, M. A., Duran, S., Kim, D. és mtsai: A comparison of twice-daily exenatide and biphasic insulin aspart in patients suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia, 2007, 50, 259-267.
49. Winkler, G.: Exenatid a klinikai gyakorlatban. Hosszabb távú alkalmazásának tapasztalatai 2-es típusú diabetesben, irodalmi áttekintés alapján. Diabetol. Hung., 2006, 14 (Suppl. 4), 5-12.
50. Petersen, K. F., Dufour, S., Befroy, D. és mtsai: Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes, 2005, 54, 603-608.